Drug intelligence / Profile preview

Hongcao Zihan Granules

Development stage: Preclinical
Lead developer: Monyan Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Hongcao Zihan Granules (红草止鼾颗粒) is a Traditional Chinese Medicine (TCM) candidate under development by Monyan Pharmaceutical. Classified as a TCM Class 2.3 therapeutic, the drug is currently in the IND-enabling phase, with clinical approval for trials expected in 2026. It is being developed for the treatment of chronic obstructive pulmonary disease (COPD) and the prevention of acute altitude sickness. The product is formulated as granules for oral administration.

Other names: 红草止鼾颗粒

Beyond the preview

Go deeper on Hongcao Zihan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hongcao Zihan Granules.

Explore the full profile